I-NEW YORK – I-Immunocore ithe ngoMvulo iza kuthengisa izabelo eziyi-3,733,333 kwisivumelwano sokuxhasa ngemali se-private equity investment (PIPE) ekulindeleke ukuba iqokelele i-$140 yezigidi.
Phantsi kwesivumelwano, i-Immunocore iza kuthengisa isitokhwe sayo esiqhelekileyo kunye nesitokhwe esiqhelekileyo esingavotelwanga nge-$37.50 ngesabelo ngasinye. Abatyali-mali benkampani abakhoyo abathatha inxaxheba kule mali baquka i-RTW Investments, iRock Springs Capital kunye neGeneral Atlantic. Isivumelwano sePIPE kulindeleke ukuba siphele ngomhla wama-20 kuJulayi.
Le nkampani iza kusebenzisa le mali ukuxhasa abaviwa bayo abaphambili kwi-oncology kunye nezifo ezisulelayo, kuquka ukuphuhliswa kwabaviwa bayo abaphambili kwi-oncology, iKimmtrak (tebentafusp-tebn), ukunyanga i-HLA-A*02:01 positive skin kunye ne-uveal melanoma. Le mali, kunye nengeniso evela kwiKimmtrak, kulindeleke ukuba ixhase imisebenzi ye-Immunocore ukuya kuthi ga ngo-2025.
Kulo nyaka, iKimmtrak ivunyiwe ukuba isetyenziswe kwizigulane ezine-HLA-A*02:01 positive unrecoctable okanye metastatic uveal melanoma e-US, eYurophu nase-UK, phakathi kwamanye amazwe. I-Immunocore iyaqhubeka nokufunda eli yeza kwisifundo seSigaba soku-1/II kwi-HLA-A*02:01-positive cutaneous melanoma.
I-Immunocore ikwaphuhlisa ezinye ii-oncology ezine, kuquka nezinye ii-T-cell receptor drugs ezimbini kwiSigaba I/II trials kwi-advanced solid tumors. Elinye lala mayeza lenzelwe izigulane ezine-HLA-A*02:01-positive kunye ne-MAGE-A4-positive, kwaye elinye lijolise kwi-HLA-A*02:01 kunye ne-PRAME-positive tumors. Le nkampani ikwanazo nee-oncology ezimbini ezingachazwanga kuphuhliso lwangaphambi kweklinikhi.
Umgaqo-nkqubo Wabucala.imigaqo neMiqathango.Ilungelo lokushicilela © 2022 GenomeWeb, iyunithi yoshishino yeCrain Communications.onke amalungelo agciniwe.